Genotype-stratified treatment for monogenic insulin resistance: a systematic review

Keyphrases

• Genotype 100%
• Insulin Resistance 100%
• Monogenic 100%
• Stratified Treatment 100%
• Lipodystrophy 85%
• Hemoglobin A1c (HbA1c) 71%
• Triglycerides 42%
• Peroxisome Proliferator-activated Receptor 42%
• Partial Lipodystrophy 42%
• Thiazolidinediones 28%
• AGPAT2 28%
• BSCL2 28%
• Metreleptin 28%
• Body Mass Index 14%
• Embase 14%
• PubMed 14%
• Inclusion Criteria 14%
• Specific Treatment 14%
• Intervention Effect 14%
• MEDLINE 14%
• Absence of Evidence 14%
• Low Hemoglobin 14%
• Genetic Etiology 14%
• Surgical Intervention 14%
• Pharmacologic 14%
• Risk of Bias 14%
• Insulin Signaling 14%
• Insulin-like Growth Factor Binding protein-3 (IGFBP-3) 14%
• Genetic Parameters 14%
• Randomized Experimental Studies 14%
• Treatment Combination 14%
• Genetic Subgroups 14%
• Metabolic Markers 14%
• Individual-level Effects 14%

Medicine and Dentistry

• Systematic Review 100%
• Insulin Resistance 100%
• Lipodystrophy 100%
• Hemoglobin A1c 62%
• Triacylglycerol 37%
• Lid Margin Neovascularized Area 37%
• Thiazolidinedione 25%
• Metreleptin 25%
• Disease 12%
• Body Mass Index 12%
• Surgery 12%
• Epileptic Absence 12%
• Insulin Signaling 12%

Biochemistry, Genetics and Molecular Biology

• Genotyping 100%
• Insulin Resistance 100%
• Glycosylated Hemoglobin 71%
• Triglyceride 42%
• LMNA 42%
• Genetics 28%
• Thiazolidinedione 28%
• BSCL2 28%
• AGPAT2 28%
• Body Mass 14%
• Medline 14%
• Insulin Signaling 14%
• Embase 14%
• IGFBP3 14%